Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab

Shadfar Bahri, Jeon Hor Chen, Rita S. Mehta, Philip M. Carpenter, Ke Nie, Soon Young Kwon, Hon J. Yu, Orhan Nalcioglu, Min Ying Su

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Purpose: To investigate the impact of antiangiogenic therapy with bevacizumab on pathological response and the diagnostic performance of magnetic resonance imaging (MRI) in breast cancer patients. Methods: Thirty-six patients (aged 31-69 years) with breast cancer were included. Sixteen patients received neoadjuvant chemotherapy (NAC) containing bevacizumab, and 20 patients received the same NAC protocol without bevacizumab. Serial MRI studies were performed to evaluate response. All patients received surgery after completing NAC. The extent of residual disease was examined by histopathology, and classified into three types (pCR-pathologic complete response, confined nodules, and scattered cells). Fisher's exact test and general logistic regression models were applied to analyze differences between two groups. Results: pCR rates and residual disease (nodular and scattered cell) patterns were comparable between the two groups. The diagnostic accuracy rate of MRI (true positive and true negative) was 13/17 (76%) for patients with bevacizumab, and 14/20 (70%) for patients without bevacizumab. The size measured on MRI was accurate for mass lesions that shrank down to nodules, showing <0.7 cm discrepancy from pathological size. For residual disease presenting as scattered cells within a large fibrotic region, MRI could not predict them correctly, resulting in a high false-negative rate and a large size discrepancy. Conclusion: The pathological response and the diagnostic performance of MRI are comparable between patients receiving NAC with and without bevacizumab. In both groups MRI has a limitation in detecting residual disease broken down to small foci and scattered cells/clusters. When MRI is used to evaluate the extent of residual disease for surgical treatment, the limitations, particularly for nonmass lesions, should be considered.

Original languageEnglish
Pages (from-to)1619-1628
Number of pages10
JournalAnnals of Surgical Oncology
Volume16
Issue number6
DOIs
Publication statusPublished - 2009 Jun 1

Fingerprint

Residual Neoplasm
Magnetic Resonance Imaging
Breast Neoplasms
Drug Therapy
Logistic Models
Bevacizumab
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. / Bahri, Shadfar; Chen, Jeon Hor; Mehta, Rita S.; Carpenter, Philip M.; Nie, Ke; Kwon, Soon Young; Yu, Hon J.; Nalcioglu, Orhan; Su, Min Ying.

In: Annals of Surgical Oncology, Vol. 16, No. 6, 01.06.2009, p. 1619-1628.

Research output: Contribution to journalArticle

Bahri, Shadfar ; Chen, Jeon Hor ; Mehta, Rita S. ; Carpenter, Philip M. ; Nie, Ke ; Kwon, Soon Young ; Yu, Hon J. ; Nalcioglu, Orhan ; Su, Min Ying. / Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. In: Annals of Surgical Oncology. 2009 ; Vol. 16, No. 6. pp. 1619-1628.
@article{c95e0f571dcb412c9552c59ae4ea61c0,
title = "Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab",
abstract = "Purpose: To investigate the impact of antiangiogenic therapy with bevacizumab on pathological response and the diagnostic performance of magnetic resonance imaging (MRI) in breast cancer patients. Methods: Thirty-six patients (aged 31-69 years) with breast cancer were included. Sixteen patients received neoadjuvant chemotherapy (NAC) containing bevacizumab, and 20 patients received the same NAC protocol without bevacizumab. Serial MRI studies were performed to evaluate response. All patients received surgery after completing NAC. The extent of residual disease was examined by histopathology, and classified into three types (pCR-pathologic complete response, confined nodules, and scattered cells). Fisher's exact test and general logistic regression models were applied to analyze differences between two groups. Results: pCR rates and residual disease (nodular and scattered cell) patterns were comparable between the two groups. The diagnostic accuracy rate of MRI (true positive and true negative) was 13/17 (76{\%}) for patients with bevacizumab, and 14/20 (70{\%}) for patients without bevacizumab. The size measured on MRI was accurate for mass lesions that shrank down to nodules, showing <0.7 cm discrepancy from pathological size. For residual disease presenting as scattered cells within a large fibrotic region, MRI could not predict them correctly, resulting in a high false-negative rate and a large size discrepancy. Conclusion: The pathological response and the diagnostic performance of MRI are comparable between patients receiving NAC with and without bevacizumab. In both groups MRI has a limitation in detecting residual disease broken down to small foci and scattered cells/clusters. When MRI is used to evaluate the extent of residual disease for surgical treatment, the limitations, particularly for nonmass lesions, should be considered.",
author = "Shadfar Bahri and Chen, {Jeon Hor} and Mehta, {Rita S.} and Carpenter, {Philip M.} and Ke Nie and Kwon, {Soon Young} and Yu, {Hon J.} and Orhan Nalcioglu and Su, {Min Ying}",
year = "2009",
month = "6",
day = "1",
doi = "10.1245/s10434-009-0441-5",
language = "English",
volume = "16",
pages = "1619--1628",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab

AU - Bahri, Shadfar

AU - Chen, Jeon Hor

AU - Mehta, Rita S.

AU - Carpenter, Philip M.

AU - Nie, Ke

AU - Kwon, Soon Young

AU - Yu, Hon J.

AU - Nalcioglu, Orhan

AU - Su, Min Ying

PY - 2009/6/1

Y1 - 2009/6/1

N2 - Purpose: To investigate the impact of antiangiogenic therapy with bevacizumab on pathological response and the diagnostic performance of magnetic resonance imaging (MRI) in breast cancer patients. Methods: Thirty-six patients (aged 31-69 years) with breast cancer were included. Sixteen patients received neoadjuvant chemotherapy (NAC) containing bevacizumab, and 20 patients received the same NAC protocol without bevacizumab. Serial MRI studies were performed to evaluate response. All patients received surgery after completing NAC. The extent of residual disease was examined by histopathology, and classified into three types (pCR-pathologic complete response, confined nodules, and scattered cells). Fisher's exact test and general logistic regression models were applied to analyze differences between two groups. Results: pCR rates and residual disease (nodular and scattered cell) patterns were comparable between the two groups. The diagnostic accuracy rate of MRI (true positive and true negative) was 13/17 (76%) for patients with bevacizumab, and 14/20 (70%) for patients without bevacizumab. The size measured on MRI was accurate for mass lesions that shrank down to nodules, showing <0.7 cm discrepancy from pathological size. For residual disease presenting as scattered cells within a large fibrotic region, MRI could not predict them correctly, resulting in a high false-negative rate and a large size discrepancy. Conclusion: The pathological response and the diagnostic performance of MRI are comparable between patients receiving NAC with and without bevacizumab. In both groups MRI has a limitation in detecting residual disease broken down to small foci and scattered cells/clusters. When MRI is used to evaluate the extent of residual disease for surgical treatment, the limitations, particularly for nonmass lesions, should be considered.

AB - Purpose: To investigate the impact of antiangiogenic therapy with bevacizumab on pathological response and the diagnostic performance of magnetic resonance imaging (MRI) in breast cancer patients. Methods: Thirty-six patients (aged 31-69 years) with breast cancer were included. Sixteen patients received neoadjuvant chemotherapy (NAC) containing bevacizumab, and 20 patients received the same NAC protocol without bevacizumab. Serial MRI studies were performed to evaluate response. All patients received surgery after completing NAC. The extent of residual disease was examined by histopathology, and classified into three types (pCR-pathologic complete response, confined nodules, and scattered cells). Fisher's exact test and general logistic regression models were applied to analyze differences between two groups. Results: pCR rates and residual disease (nodular and scattered cell) patterns were comparable between the two groups. The diagnostic accuracy rate of MRI (true positive and true negative) was 13/17 (76%) for patients with bevacizumab, and 14/20 (70%) for patients without bevacizumab. The size measured on MRI was accurate for mass lesions that shrank down to nodules, showing <0.7 cm discrepancy from pathological size. For residual disease presenting as scattered cells within a large fibrotic region, MRI could not predict them correctly, resulting in a high false-negative rate and a large size discrepancy. Conclusion: The pathological response and the diagnostic performance of MRI are comparable between patients receiving NAC with and without bevacizumab. In both groups MRI has a limitation in detecting residual disease broken down to small foci and scattered cells/clusters. When MRI is used to evaluate the extent of residual disease for surgical treatment, the limitations, particularly for nonmass lesions, should be considered.

UR - http://www.scopus.com/inward/record.url?scp=67349187877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349187877&partnerID=8YFLogxK

U2 - 10.1245/s10434-009-0441-5

DO - 10.1245/s10434-009-0441-5

M3 - Article

VL - 16

SP - 1619

EP - 1628

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 6

ER -